Inhibikase Therapeutics Inc (IKT) USD0.001

- Add to watchlist
- This stock can be held in a




Business summary
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company's product candidates include IkT-148009, IkT-001Pro and IKT-01427. Its lead product candidate, IkT-148009 is a brain penetrant Abelson tyrosine kinase (c-Abl) inhibitor, that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the gastrointestinal (GI) tract. Its IkT-148009 is for the treatment of PD, including its manifestation in the GI tract. Its product candidate IkT-001Pro, is a prodrug of the anticancer agent Imatinibm, which is used as a treatment for chronic myelogenous leukemia (CML). IkT-01427 is an oral, brain-penetrant medication, designed to block the entry of the John Cunningham (JC) virus into the cell, thereby preventing the virus’ ability to replicate in the body.
Contact details
Important dates
General stock information
- Short code:
- IKT
- ISIN:
- US45719W1062
- Market cap:
- $19.17 million
- Shares in issue:
- 25.23 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.